• Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Biosimilarity: The FDA Perspective

Biosimilarity: The FDA Perspective

Hardcover

Medical Reference

ISBN10: 1498750397
ISBN13: 9781498750394
Publisher: Crc Pr Inc
Published: Jul 25 2018
Pages: 398
Weight: 2.40
Height: 1.10 Width: 7.30 Depth: 10.00
Language: English

Summary:

The focus of this book is on how the U.S. FDA will approve biosimilar drugs, as learned from recent approvals by the FDA. Understanding the limitations of the statutory limits and non-inferiority testing are presented as tools to obviate patient trials and minimize testing of immunogenicity. An in-depth scientific, mathematical and statistical view of the tools required to establish biosimilarity of biological drugs of different complexity -- a must for every developer of biosimilars.

1 different editions

Also available

Also in

Medical Reference